Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000220 · ClinicalTrials.gov registry record · Phase 1

Gradual Vs. Rapid Buprenorphine Detoxification - 2

A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 1
Development phase

NCT00000220: Completed Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00000220 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000220, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.

Interventions

  • DRUG Buprenorphine

Trial Details

FieldValue
Start Date 1991-06
Est. Completion 2001-07
Phase Phase 1

What the finished NCT00000220 record still lists

NCT00000220 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which Buprenorphine is the first listed.

NCT00000220 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000220 about?

NCT00000220 is a clinical study titled "Gradual Vs. Rapid Buprenorphine Detoxification - 2". The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.

What is the current status of trial NCT00000220?

This trial is currently completed. It is a Phase 1 study. The study started on 1991-06. Estimated completion is 2001-07.

What interventions are being tested in trial NCT00000220?

The interventions under investigation include: Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT00000220?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00000220, the US trial registry maintained by the National Library of Medicine. NCT00000220 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.